Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC

Hepatocellular Carcinoma Clinical Trial

Official title:

A Multi-center, Phase 1b/2 Study for Autologous T Cells Transfected With mRNA Encoding HBV Antigen-specific TCR (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for Advanced HBV-related Hepatocellular Carcinoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05195294
• Other study ID #: LTCR-HCC-3-4
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: June 2022
• Est. completion date: May 2027

Study information

• Verified date: December 2021
• Source: Lion TCR Pte. Ltd.
• Contact: Royce Fam
• Phone: +65 6926 0818
• Email: royce.fam[@]liontcr.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm, open-label and multi-center Phase 1b/2 study to evaluate the safety and efficacy of autologous T-cells transfected with mRNA encoding Hepatitis-B virus (HBV)-antigen-specific T cell receptor (TCR) (LioCyx-M) as monotherapy or as combination with lenvatinib for the treatment of advanced HBV-related hepatocellular carcinoma (HCC).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 55
• Est. completion date: May 2027
• Est. primary completion date: February 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Eastern Cooperative Oncology Group (ECOG) performance status =1

2. Advanced HCC with diagnosis confirmed by histology/ cytology or clinically by AASLD criteria in cirrhotic patients.

3. Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies

4. Patients who failed first-line systemic therapy for HCC

5. Serum HBsAg positivity

6. Non-cirrhotic or compensated cirrhosis Child-Pugh A (5 - 6 points)

7. HLA class 1 profile matching HLA-class I restriction element of the available T cell receptor

Exclusion Criteria:

1. Brain metastasis

2. Second primary malignancy that is clinically detectable at the time of consideration for study enrolment, except for in situ carcinoma of the cervix, non-melanoma skin carcinoma localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer and superficial bladder tumours.

3. Lack of peripheral venous or central venous access or any condition that would interfere with drug administration or collection of study samples

4. History of severe allergic anaphylactic reactions to T cell therapy products and/or lenvatinib

5. Local or loco-regional therapy of intrahepatic tumour lesions (e.g. surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed =4 weeks before the first infusion of LioCyx-M.

6. Concurrent administration of any other anti-tumour therapy, including cytotoxic chemotherapy, tyrosine kinase inhibitor therapy, and immunotherapy.

7. Treatment with anticancer therapy, including investigational therapy, within 2 weeks prior to first infusion. For prior therapies with a half-life longer than 3 days, discontinuation of the therapy must have occurred at least 28 days prior to leukapheresis.

8. Treatment with other investigational therapy within 28 days prior to initiation of study treatment. Patients participating in surveys or observational studies are eligible to participate in this study.

9. Likelihood to require any immunosuppressive treatments during the period of the clinical trial (Localized steroid use should be allowed)

10. Human immunodeficiency virus (HIV) positive or active infection requiring treatment (except for HBV)

11. Significant cardiovascular disease (such as New York Heart Association (NYHA) Functional Classification Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment), unstable arrhythmia, or unstable angina

12. Uncontrolled hypertension, defined as systolic blood pressure >160 mmHg or diastolic pressure >110 mmHg, despite optimal medical management

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma
• Liver Cancer, Adult
• Liver Cell Carcinoma

Intervention

Biological:
• LioCyx-M
HBV antigen specific TCR redirected T cells

Drug:
• Lenvatinib
12 mg once daily for patients =60 kg, 8 mg for patients <60kg by oral

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Lion TCR Pte. Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessments of adverse events/serious adverse events	To evaluate the safety of LioCyx-M as a monotherapy and in combination with lenvatinib	Up to 4 years from study treatment initiation
Primary	Objective response rate (ORR)	To evaluate the anti-tumor efficacy of LioCyx-M as a monotherapy and in combination with lenvatinib	Up to 4 years from study treatment initiation
Secondary	Progression free survival (PFS)	To evaluate the anti-tumor efficacy of LioCyx-M as a monotherapy and in combination with lenvatinib	Up to 4 years from study treatment initiation
Secondary	Time to radiographic progression (TTRP)	To evaluate the anti-tumor efficacy of LioCyx-M as a monotherapy and in combination with lenvatinib	Up to 4 years from study treatment initiation
Secondary	Duration of response (DoR)	To evaluate the anti-tumor efficacy of LioCyx-M as a monotherapy and in combination with lenvatinib	Up to 4 years from study treatment initiation
Secondary	Overall survival (OS)	To evaluate the anti-tumor efficacy of LioCyx-M as a monotherapy and in combination with lenvatinib	Up to 4 years from study treatment initiation